Search

Search Constraints

You searched for: Author/Creator Berg, S

Search Results

12. OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn's disease by number and type of prior biologics. (30th January 2023)

13. OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. (27th May 2021)

14. OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. (27th May 2021)

15. P274 Factors driving treatment escalation in Crohn's disease in the CALM trial. (16th January 2018)

16. P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn's disease. (30th January 2023)

17. P522 Upadacitinib Promotes Histologic and Endoscopic Mucosal Healing: Results from the Upadacitinib Ulcerative Colitis Phase 3 Program. (21st January 2022)

18. P757 Long-term effectiveness and safety of adalimumab based on Crohn's disease duration: Results from the PYRAMID registry. (16th January 2018)